Form 4: Director Azelby Acquires and Sells ADC Therapeutics Shares

Robert Azelby, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of restricted stock units and the sale of common shares.

Summary

• Robert Azelby, a Director at ADC Therapeutics SA (ADCT), acquired 45,000 restricted stock units (RSUs) on June 1, 2026, as part of his annual grant for director services. These RSUs vest one year from the grant date or at the 2027 Annual Meeting of Shareholders, contingent on continued service.
• On June 3, 2026, Azelby disposed of 12,600 common shares. This disposal was to cover tax withholding obligations related to the vesting of previously granted restricted share units.
• Following these transactions, Azelby beneficially owns 112,805 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions reported are routine insider compensation and tax-related share disposals, with no indication of significant buying or selling based on non-public information.

Positives

• Director Azelby received an annual grant of 45,000 RSUs, indicating continued compensation and incentive for service.
• The RSUs are structured to vest over time, aligning the director's interests with the company's long-term performance.
• The disposal of shares was for tax withholding, a standard and expected transaction upon vesting of equity awards.

Negatives

• Director Azelby sold 12,600 common shares, which could be interpreted as a reduction in direct ownership, although it was for tax purposes.

Risks

• The vesting of RSUs is contingent on the Reporting Person's continued service, implying a risk of forfeiture if service is terminated before vesting.
• Future tax withholding obligations could lead to further disposals of common shares by the director.

Future Outlook

The RSUs granted to Robert Azelby are set to vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, subject to his continued service. This indicates a forward-looking incentive tied to ongoing commitment.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported by Director Azelby, are common for executives and directors receiving equity-based compensation. The acquisition of RSUs reflects standard compensation practices in the biotechnology and pharmaceutical sectors, while the sale for tax withholding is a routine event.

Related Party Transactions

• The acquisition of 45,000 RSUs by Director Robert Azelby represents a transaction between the issuer and a related party (director).

Stakeholder Impact

• Shareholders: The transactions are routine and do not suggest a change in the director's overall commitment or belief in the company's prospects. The disposal was for tax purposes, not a sale of shares based on market outlook.
• Employees: The RSU grant to the director aligns with broader equity incentive practices that may also apply to employees, reinforcing a culture of shared ownership and performance.
• Management: The transaction reflects standard compensation and governance practices for directors.

Next Steps

• Continued service by Robert Azelby to meet vesting requirements for the granted RSUs.
• Potential vesting of RSUs on or before the 2027 Annual Meeting of Shareholders.
• Future tax withholding obligations may lead to additional share disposals.

Key Dates

Keywords

ADC Therapeutics, ADCT, Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Share Vesting, Tax Withholding, Beneficial Ownership